Racial Differences in Multiple Myeloma Survival and Treatment Using Pooled Clinical Trial and Real-World Electronic Medical Record Data

EmellyRusli*¹LihongDiaoMDMS*²CynthiaLiu*³⁴Mona AKelkarMBA*³⁵LisaEnsignPhDMS*²MarkWatsonMDPhD*⁶AaronGalaznikMDMBA¹

Clinical validation of a targeted methylation-based multi-cancer early detection test using an independent validation set

E. A. Klein, D. Richards, A. Cohn, M. Tummala, R. Lapham, D. Cosgrove, G. Chung, J. Clement, J. Gao, N. Hunkapiller, A. Jamshidi, K. N. Kurtzman, M. V. Seiden, C. Swanton & M. C. Liu

Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland; The US Oncology Network, Tyler; The US Oncology Network, Denver; Mercy Clinic Cancer Center, Springfield; Spartanburg Regional Healthcare System, Spartanburg; Compass Oncology, Vancouver; The Christ Hospital Health Network, Cincinnati; Hartford HealthCare Cancer Institute, Hartford; GRAIL, Inc., Menlo Park; US Oncology Research, The Woodlands, USA; The Francis Crick Institute, London; University College London Cancer Institute, London, UK; Mayo Clinic, Rochester, USA

(Bold indicates GRN Partner Health Systems)

Evaluating progression-free survival in black and white women with triple-negative breast cancer in pooled clinical trials from a synthetic control database (SCD) and real-world electronic medical records (EMR).

Mark Layton Watson, Kevin Holcomb, Lisa Newman, Janna Andrews, Lisa Ensign, Aaron Galaznik, Bryant Fields, Sheila Diamond, Nicole Pollard

Assessing the relationship in relapsed-refractory multiple myeloma between response, progression, and survival between pooled clinical trial subjects and a real-world electronic medical record data source

Mark Layton Watson, Charlie Hurmiz, Jordan Smith, Suresh Marada, Aaron Galaznik, Sheila Diamond, Bryant Fields, Ruthanna Davi

Effect of access to care on outcomes of rural and elderly patients with primary central nervous system lymphoma

Scott C. Howard, Nicholas Napier, Xueyuan Cao, Ryan Combs, Mark Layton Watson, and Catherine Lam

Use of real-world data and machine learning to reduce treatment-limiting adverse events in an acute myeloid leukemia clinical trail population

R. Buderi, J. Ransom, A. Galaznik, M. Berger

Tumor Lysis Syndrome Management in Community Oncology Settings

Scott Howard

Management of Delayed Elimination of High-Dose Methotrexate in Community Oncology Practices Can Mitigate Its Effect on Length of Hospital Stay, Treatment Dose-Density, Acute Kidney Injury, Dialysis, and Death

Scott Howard, McKeon Tad Harry, Sfondouris John, Suresh Marada, Nicholas Napier

Pattern of rasburicase (RAS) use in community oncology programs and impact on tumor lysis syndrome (TLS) outcomes

Wynter Balcerski, Scott C. Howard, Nicholas Napier